Comparative safety of antiepileptic drugs for neurological development in children exposed during pregnancy and breast feeding: a systematic review and network meta-analysis
Open accessThe DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index; 8 of the 28 sources its claims cite were checked for support.
Abstract
Objectives: Compare the safety of antiepileptic drugs (AEDs) on neurodevelopment of infants/children exposed in utero or during breast feeding. Design and setting: Systematic review and Bayesian random-effects network meta-analysis (NMA). MEDLINE, EMBASE and the Cochrane Central Register of Controlled Trials were searched until 27 April 2017. Screening, data abstraction and quality appraisal were completed in duplicate by independent reviewers. Participants: 29 cohort studies including 5100 infants/children. Interventions: Monotherapy and polytherapy AEDs including first-generation (carbamazepine, clobazam, clonazepam, ethosuximide, phenobarbital, phenytoin, primidone, valproate) and newer-generation (gabapentin, lamotrigine, levetiracetam, oxcarbazepine, topiramate, vigabatrin) AEDs. Epileptic women who did not receive AEDs during pregnancy or breast feeding served as the control group. Primary and secondary outcome measures: Cognitive developmental delay and autism/dyspraxia were primary outcomes. Attention-deficit hyperactivity disorder, language delay, neonatal seizures, psychomotor developmental delay and social impairment were secondary outcomes. Results: The NMA on cognitive developmental delay (11 cohort studies, 933 children, 18 treatments) suggested that among all AEDs only valproate was statistically significantly associated with more children experiencing cognitive developmental delay compared with control (OR=7.40, 95% credible interval (CrI) 3.00 to 18.46). The NMA on autism (5 cohort studies, 2551 children, 12 treatments) suggested that oxcarbazepine (OR 13.51, CrI 1.28 to 221.40), valproate (OR 17.29, 95% CrI 2.40 to 217.60), lamotrigine (OR 8.88, CrI 1.28 to 112.00) and lamotrigine+valproate (OR 132.70, CrI 7.41 to 3851.00) were associated with significantly greater odds of developing autism compared with control. The NMA on psychomotor developmental delay (11 cohort studies, 1145 children, 18 treatments) found that valproate (OR 4.16, CrI 2.04 to 8.75) and carbamazepine+phenobarbital+valproate (OR 19.12, CrI 1.49 to 337.50) were associated with significantly greater odds of psychomotor delay compared with control. Conclusions: Valproate alone or combined with another AED is associated with the greatest odds of adverse neurodevelopmental outcomes compared with control. Oxcarbazepine and lamotrigine were associated with increased occurrence of autism. Counselling is advised for women considering pregnancy to tailor the safest regimen. Trial registration number: PROSPERO database (CRD42014008925).
Overview
CoChat Summary
TL;DR
This systematic review and Bayesian network meta-analysis of 29 cohort studies (5100 children) found that valproate alone or combined with another AED was associated with the greatest odds of adverse neurodevelopmental outcomes. Oxcarbazepine and lamotrigine were also associated with increased autism/dyspraxia.
Key findings
- Cognitive developmental delay NMA (11 cohort studies, 933 children, 18 treatments): only valproate was significantly associated with more children experiencing cognitive developmental delay versus control (OR 7.40, 95% CrI 3.00 to 18.46).
- Autism/dyspraxia NMA (5 cohort studies, 2551 children, 12 treatments): oxcarbazepine (OR 13.51, CrI 1.28 to 221.40), valproate (OR 17.29, 95% CrI 2.40 to 217.60), lamotrigine (OR 8.88, CrI 1.28 to 112.00) and lamotrigine+valproate (OR 132.70, CrI 7.41 to 3851.00) were associated with significantly greater odds of autism/dyspraxia versus control.
- Psychomotor developmental delay NMA (11 cohort studies, 1145 children, 18 treatments): valproate (OR 4.16, CrI 2.04 to 8.75) and carbamazepine+phenobarbital+valproate (OR 19.12, CrI 1.49 to 337.50) were associated with significantly greater odds versus control.
- Language delay NMA (5 cohort studies, 509 children, 5 treatments): valproate was the only treatment significantly associated with increased odds (OR 7.95, 95% CrI 1.50 to 49.13). ADHD NMA (5 cohort studies, 816 children, 7 treatments) found no treatment comparisons reached statistical significance.
Methods
- Systematic review and Bayesian random-effects network meta-analysis; MEDLINE, EMBASE and Cochrane Central Register of Controlled Trials searched until 27 April 2017; screening, data abstraction and quality appraisal completed in duplicate; registered with PROSPERO (CRD42014008925).
- Included 29 cohort studies (5100 infants/children) of mothers consuming AEDs during pregnancy and/or breastfeeding; monotherapy and polytherapy first-generation and newer-generation AEDs were eligible; control was epileptic women who did not receive AEDs; primary outcomes were cognitive developmental delay and autism/dyspraxia, with secondary outcomes including ADHD, language delay, neonatal seizures, psychomotor developmental delay and social impairment.
- Used ORs for dichotomous outcomes, hierarchical meta-analysis and NMA models in a Bayesian framework (OpenBUGS), random-effects models, transitivity and consistency assessments, network meta-regression and sensitivity analyses, and SUCRA rankings.
Limitations
- Stated in the paper: drug dosages could not be accounted for, and different dosages of the same AED were assumed equally effective; when a study reported multiple dosages for the same treatment, data were combined.
- Stated in the paper: several polytherapies had high SUCRA estimates but very wide credible intervals due to small numbers of studies and underpowered sample sizes; ranking probabilities may be biased toward treatments with the smallest number of studies.
- Stated in the paper: no RCT evidence was available, so conclusions were based on observational studies only, with inherent confounding and shortcomings; important effect modifiers were often unreported (eg, family history of autism, ADHD, maternal IQ, severity of epilepsy), and subgroup analysis by exposure type (breastfeeding vs in utero) could not be conducted because 22 studies did not report breastfeeding exposure. Evident from the text: many NMAs included small numbers of studies/children, credible intervals were wide, and methodological quality was imbalanced across treatment comparisons.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
5 Valid · 0 Not valid · 13 Not checked · 67 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“AED use during pregnancy is associated with risks to the fetus as these drugs can cross the placenta or may be transferred to the infant through breast feeding and may be associated with adverse neurodevelopment outcomes.2–4”
§ Comparative safety of antiepileptic drugs for neurological development in children exposed during pregnancy and breast feeding: a systematic review and network meta-analysis > Introduction
What the sources say
- Partly supportedcites [2] matched to “Management issues for women with epilepsy—Focus on pregnancy (an evidence‐based review): III. Vitamin K, folic acid, blood levels, and breast‐feeding: Report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the American Epilepsy Society” (2009) sourceExperimental — accuracy not yet measured
The Conclusions and Clinical context sections report that many AEDs cross the placenta or enter breast milk. But Recommendations for Future Research says studies did not systematically evaluate outcomes such as cognition and neonatal development. This source therefore supports the exposure pathways, not an association with adverse neurodevelopmental outcomes. (LLM, conf=0.86)
- Could not verifycites [3] matched to “Maternal Use of Antiepileptic Drugs and the Risk of Major Congenital Malformations: A Joint European Prospective Study of Human Teratogenesis Associated with Maternal Epilepsy” (1997) sourceExperimental — accuracy not yet measured
The Abstract and Results report an association between prenatal AED exposure and major congenital malformations, not adverse neurodevelopmental outcomes. A search for cognitive or developmental outcomes found no assessment of those outcomes in our copy; congenital malformations alone do not establish the attributed neurodevelopmental association. (LLM, conf=0.76)
- Could not verifycites [4] matched to “Pregnancy outcomes in women with epilepsy: A systematic review and meta-analysis of published pregnancy registries and cohorts” (2008) sourceExperimental — accuracy not yet measured
The Introduction and Discussion address congenital malformations and other pregnancy outcomes associated with in-utero AED exposure, but do not report neurodevelopmental outcomes in children. Searches for neurodevelopment, cognition, and developmental delay found no passage in the paper's substantive text that establishes the claimed association. (LLM, conf=0.76)
hedgedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“However, there is a lack of sufficiently powered studies to assess the impact of AEDs on neurodevelopment in children of women exposed to these agents, especially for newer-generation drugs, thus highlighting the need for a systematic review.9 10”
§ Comparative safety of antiepileptic drugs for neurological development in children exposed during pregnancy and breast feeding: a systematic review and network meta-analysis > Introduction
What the sources say
- Partly supportedcites [9] Wlodarczyk, 2012, Antiepileptic drugs and pregnancy outcomes, Am J Med Genet A sourceExperimental — accuracy not yet measured
The Introduction (page unavailable) says most studies of AED teratogenic effects are too small and underpowered, and that risks of newer drugs remain unknown because of small sample sizes and polytherapy exposure. It also discusses neurodevelopmental deficits after valproate exposure, but the cited passages do not specifically establish a lack of sufficiently powered studies of children’s neurodevelopment, particularly for newer-generation AEDs. (LLM, conf=0.84)
- Supportedcites [10] Velez-Ruiz, 2015, Neurodevelopmental effects of fetal antiepileptic drug exposure, Drug Saf source
The Human Studies limitations section says some studies had small samples and that large studies are needed to assess less frequent outcomes. The Conclusions section says the cognitive and behavioral risks of fetal exposure to other AEDs remain unknown because adequate human data are lacking, supporting the particular concern about newer drugs. The cited paper does report established findings for some AEDs, so the claim is best read as a statement about gaps in the evidence, not a complete absence of studies. (LLM, conf=0.88)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Our results are supported by findings from a cohort study, which found that children exposed to levetiracetam were not at increased risk for delayed development compared with unexposed children (see online supplementary appendix C).42”
§ Comparative safety of antiepileptic drugs for neurological development in children exposed during pregnancy and breast feeding: a systematic review and network meta-analysis > Discussion
What the sources say
- Supportedcites [42] matched to “Child development following in utero exposure: Levetiracetam vs sodium valproate” (2011) source
The Abstract (Conclusion) of our copy states directly that children exposed to LEV in utero are not at increased risk of delayed development, and the Results (p. ~7, passage on overall developmental ability) show LEV-exposed children did not differ from the control group (p = 0.62), with 8% below average vs 12% in controls. The control group is defined in Methods as children born to women without epilepsy and not exposed to medication in pregnancy (n = 97), i.e. unexposed children, and the study is described as a prospective observational cohort recruited from 2 UK cohorts, matching 'cohort study'. The only qualifier the citing sentence drops is the source's age/domain bound ('early cognitive development under the age of 24 months'), which does not alter the attributed comparison. (LLM, conf=0.92)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The NMA on cognitive developmental delay (11 cohort studies, 933 children, 18 treatments) suggested that among all AEDs only valproate was statistically significantly associated with more children experiencing cognitive developmental delay compared with control (OR=7.40, 95% credible interval (CrI) 3.00 to 18.46).”
- Also stated in: § Cognitive developmental delay · plain
“Across all AEDs, only valproate was associated with significantly increased odds of cognitive developmental delay compared with control (OR 7.40, 95% CrI 3.00 to 18.46; figure 2A; see online supplementary appendix H).”
§ Comparative safety of antiepileptic drugs for neurological development in children exposed during pregnancy and breast feeding: a systematic review and network meta-analysis > Abstract > Results
plainstates an associationn = 933- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on 2 assumptions not shown here.
- Also stated in: § Cognitive developmental delay · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“29 cohort studies including 5100 infants/children.”
- Also stated in: § Study and patient characteristics · plain
“We included 29 cohort studies (5100 patients) published between 1989 and 2016”
- Also stated in: § Trial registration number · plain
“Twenty-nine cohort studies involving 5100 children of women who took antiepileptic drugs (AEDs) were included in this systematic review.”
§ Comparative safety of antiepileptic drugs for neurological development in children exposed during pregnancy and breast feeding: a systematic review and network meta-analysis > Abstract > Participants
plainn = 5,100- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Study and patient characteristics · plain
40 more claims
Create a free account to see all 85 claims and to verify the 20 references still open.
- Probably not a substantial claim. 19
- It may state two separate claims as one. 24
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Important is also that the anti-epileptic drugs, given at young age or during pregnancy, can have major neurodevelopmental implications as well.”
From Development of prefrontal cortex (2022) · cites this paper as [393]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“reporting that only valproate was associated with more children experiencing cognitive developmental delay compared with controls (OR 7.40, 95% CI 3.00–18.46).”
From The contribution of environmental exposure to the etiology of autism spectrum disorder (2019) · cites this paper as [128]
In the citing paper
“In a subset of studies examining autism risk (5 cohort studies, 2551 children, 12 treatments), this risk was amplified (OR 17.29, 95% CI 2.40–217.60) [128].”
From The contribution of environmental exposure to the etiology of autism spectrum disorder (2019) · cites this paper as [128]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“| Cognitive developmental delay | 12 | 58.62 |”
§ Comparative safety of antiepileptic drugs for neurological development in children exposed during pregnancy and breast feeding: a systematic review and network meta-analysis > Results > Study and patient characteristics
Reported 58.62 · recomputed 41.37931
Citations
Cites
Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series
(2008) · doi:10.1002/9780470712184 · Cited by 25,048 · cited 1×
“Strengths of our study include a comprehensive systematic review methodology that followed the Cochrane Handbook 44 and ISPOR 12 guidelines, and reported using the PRISMA extension for NMA.”
MethodDermyshi, E., Wang, Y., Yan, C., Hong, W., Qiu, G., Gong, X., & Zhang, T. (2017) · Neonatology · doi:10.1159/000454668 · Cited by 24,451
(2014) · Medical Entomology and Zoology · Cited by 17,633
Hutton, B., Salanti, G., Caldwell, D. M., Chaimani, A., Schmid, C. H., Cameron, C., Ioannidis, J. P. A., Straus, S., Thorlund, K., Jansen, J. P., et al. (2015) · Annals of Internal Medicine · doi:10.7326/m14-2385 · Cited by 8,269 · cited 3×
“Strengths of our study include a comprehensive systematic review methodology that followed the Cochrane Handbook(44) and ISPOR(12) guidelines, and reported using the PRISMA extension for NMA.(13) To the best of our knowledge, our study was the first that compared and ranked the safety of AEDs.”
MethodSelf-citationPRESS Peer Review of Electronic Search Strategies: 2015 Guideline Statement
McGowan, J., Sampson, M., Salzwedel, D. M., Cogo, E., Foerster, V., & Lefebvre, C. (2016) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2016.01.021 · Cited by 5,700 · cited 1×
“The search strategy for MEDLINE was peer-reviewed by another librarian using the Peer Review of Electronic Search Strategies (PRESS) checklist 15 and is available in the protocol.”
MethodSelf-citationSalanti, G., Ades, A. E., & Ioannidis, J. P. A. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.03.016 · Cited by 3,766
Publication bias in clinical research
Easterbrook, P. J., Gopalan, R., Berlin, J. A., & Matthews, D. R. (1991) · The Lancet · doi:10.1016/0140-6736(91)90201-y · Cited by 3,109 · cited 1×
“Fifth, although the tendency towards small-study effects is greater with observational studies than with randomised trials, 50 the assessment of small-study effects using adjusted funnel plots suggested no evidence for their prevalence.”
BackgroundInterpretation of random effects meta-analyses
Riley, R. D., Higgins, J. P. T., & Deeks, J. J. (2011) · BMJ · doi:10.1136/bmj.d549 · Cited by 2,884 · cited 1×
“28 29 The estimated safety of the included AEDs was ranked using the surface under the cumulative ranking (SUCRA) curve.”
MethodA Re-Evaluation of Random-Effects Meta-Analysis
Higgins, J. P. T., Thompson, S. G., & Spiegelhalter, D. J. (2009) · Journal of the Royal Statistical Society Series A: Statistics in Society · doi:10.1111/j.1467-985x.2008.00552.x · Cited by 2,569 · cited 1×
“28 29 The estimated safety of the included AEDs was ranked using the surface under the cumulative ranking (SUCRA) curve.”
MethodGraphical tools for network meta-analysis in STATA
Chaimani, A., Higgins, J. P. T., Mavridis, D., Spyridonos, P., & Salanti, G. (2013) · PLoS ONE · doi:10.1371/journal.pone.0076654 · Cited by 2,473 · cited 1×
“16 For each outcome with ≥ 10 studies, the comparison-adjusted funnel plot was used to assess small-study effects, 17 where the overall treatment effect for each comparison was estimated under the fixed-effect meta-analysis model.”
MethodCombination of direct and indirect evidence in mixed treatment comparisons
Lu, G., & Ades, A. E. (2004) · Statistics in Medicine · doi:10.1002/sim.1875 · Cited by 2,166 · cited 1×
“An NMA was applied for connected evidence networks and prespecified treatment nodes.(19) We assessed the transitivity assumption for each outcome a priori using the effect modifiers: age, baseline risk, treatment indication, timing and methodological quality.”
MethodThe BUGS project: evolution, critique and future directions
Lunn, D., Spiegelhalter, D., Thomas, A., & Best, N. (2009) · Statistics in Medicine · doi:10.1002/sim.3680 · Cited by 1,876 · cited 1×
“24 25 All analyses were conducted in OpenBUGS 26 assuming non-informative priors for all model parameters, and τ ~ Ν (0,1), τ >0.”
MethodPrenatal Valproate Exposure and Risk of Autism Spectrum Disorders and Childhood Autism
Christensen, J., Grønborg, T. K., Sørensen, M. J., Schendel, D., Parner, E. T., Pedersen, L. H., & Vestergaard, M. (2013) · JAMA · doi:10.1001/jama.2013.2270 · Cited by 1,357
White, I. R., Barrett, J. K., Jackson, D., & Higgins, J. P. T. (2012) · Research Synthesis Methods · doi:10.1002/jrsm.1045 · Cited by 1,114 · cited 1×
“The consistency assumption was evaluated for the entire network of each outcome using the random-effects design-by-treatment interaction model when multiple studies were available in each network design or the fixed-effect design-by-treatment interaction model when a single study informed each network design.(21) If i…”
MethodSong, F., Altman, D. G., Glenny, A.-M., & Deeks, J. J. (2003) · BMJ · doi:10.1136/bmj.326.7387.472 · Cited by 943 · cited 1×
“If inconsistency was identified, further examination for local inconsistency in parts of the network was completed using the loop-specific method.(22) 23 Common within-network between-study variance (τ(2)) across treatment comparisons was assumed in the meta-analysis, NMA and design-by-treatment interaction model so t…”
MethodMeador, K. J., Baker, G. A., Browning, N., Cohen, M. J., Bromley, R. L., Clayton-Smith, J., Kalayjian, L. A., Kanner, A., Liporace, J. D., Pennell, P. B., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70323-x · Cited by 834 · cited 1×
“Our results are consistent with a longitudinal study of 311 children that found exposure to lamotrigine was associated with significantly higher IQ scores and verbal function at 6 years of age compared with children exposed to valproate (see online supplementary appendix C).(7) As indicated in the online supplementary…”
ResultJansen, J. P., & Naci, H. (2013) · BMC Medicine · doi:10.1186/1741-7015-11-159 · Cited by 656 · cited 1×
“The mean of each continuous effect modifier and the mode of each categorical effect modifier for each pairwise comparison were presented in tables for each outcome.(20) The consistency assumption was evaluated for the entire network of each outcome using the random-effects design-by-treatment interaction model when mu…”
MethodThe longer term outcome of children born to mothers with epilepsy
Adab, N. (2004) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2003.029132 · Cited by 580
Evaluation of inconsistency in networks of interventions
Veroniki, A. A., Vasiliadis, H. S., Higgins, J. P., & Salanti, G. (2013) · International Journal of Epidemiology · doi:10.1093/ije/dys222 · Cited by 576 · cited 1×
“22 23 Common within-network between-study variance ( τ 2 ) across treatment comparisons was assumed in the meta-analysis, NMA and design-by-treatment interaction model so that treatment comparisons including a single study can borrow strength from the remaining network.”
BackgroundSelf-citationSamrén, E. B., van Duijn, C. M., Koch, S., Hiilesmaa, V. K., Klepel, H., Bardy, A. H., Mannagetta, G. B., Deichl, A. W., Gaily, E., Granström, I. L., et al. (1997) · Epilepsia · doi:10.1111/j.1528-1157.1997.tb01480.x · Cited by 406
Meador, K., Reynolds, M. W., Crean, S., Fahrbach, K., & Probst, C. (2008) · Epilepsy Research · doi:10.1016/j.eplepsyres.2008.04.022 · Cited by 400
Meta-analysis in Stata : an updated collection from the Stata journal
Palmer, T., & Sterne, J. A. C. (2015) · Medical Entomology and Zoology · Cited by 388
Veroniki, A. A., Cogo, E., Rios, P., Straus, S. E., Finkelstein, Y., Kealey, R., Reynen, E., Soobiah, C., Thavorn, K., Hutton, B., et al. (2017) · BMC Medicine · doi:10.1186/s12916-017-0845-1 · Cited by 339
Self-citationJansen, J. P., Trikalinos, T., Cappelleri, J. C., Daw, J., Andes, S., Eldessouki, R., & Salanti, G. (2014) · Value in Health · doi:10.1016/j.jval.2014.01.004 · Cited by 319
Furukawa, T. A., Guyatt, G. H., & Griffith, L. E. (2002) · International Journal of Epidemiology · doi:10.1093/ije/31.1.72 · Cited by 318 · cited 1×
“across studies, and to achieve the highest generalisability in the meta-analytical treatment effects, we applied a random-effects model.(18) An NMA was applied for connected evidence networks and prespecified treatment nodes.”
MethodTreatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child
Bromley, R., Weston, J., Adab, N., Greenhalgh, J., Sanniti, A., McKay, A. J., Tudur Smith, C., & Marson, A. G. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010236.pub2 · Cited by 277 · cited 3×
“Similarly, two previous systematic reviews that did not conduct an NMA found valproate was associated with significantly lower IQ scores and poorer overall neurodevelopmental outcomes compared with an unexposed control group.(5) 6 Also consistent with our results, a 2014 Cochrane review including 28 studies (10 of the…”
BackgroundResultInfluentialLong term health and neurodevelopment in children exposed to antiepileptic drugs before birth
Dean, J. C. S., Hailey, H., Moore, S. J., Lloyd, D. J., Turnpenny, P. D., & Little, J. (2002) · Journal of Medical Genetics · doi:10.1136/jmg.39.4.251 · Cited by 252
Antiepileptic drugs: indications other than epilepsy
Spina, E., & Perugi, G. (2004) · Epileptic Disorders · doi:10.1684/j.1950-6945.2004.tb00053.x · Cited by 235 · cited 1×
“InTroducTIon Antiepileptic drugs (AEDs) are used by pregnant women for various conditions, such as epilepsy, pain syndromes, psychiatric disorders and chronic migraine.(1) AED use during pregnancy is associated with risks to the fetus as these drugs can cross the placenta or may be transferred to the infant through br…”
BackgroundVeroniki, A. A., Straus, S. E., Fyraridis, A., & Tricco, A. C. (2016) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2016.02.016 · Cited by 219
Self-citationEvidence Synthesis for Decision Making in Healthcare
Welton, N. J., Sutton, A. J., Cooper, N. J., Abrams, K. R., & Ades, A. E. (2012) · Wiley eBooks · doi:10.1002/9781119942986 · Cited by 216
Uncertainty in Treatment Rankings: Reanalysis of Network Meta-analyses of Randomized Trials
Trinquart, L., Attiche, N., Bafeta, A., Porcher, R., & Ravaud, P. (2016) · Annals of Internal Medicine · doi:10.7326/m15-2521 · Cited by 202
Combining randomized and non-randomized evidence in network meta-analysis
Efthimiou, O., Mavridis, D., Debray, T. P. A., Samara, M., Belger, M., Siontis, G. C. M., Leucht, S., Salanti, G., & 4, O. B. O. G. W. P. (2017) · Statistics in Medicine · doi:10.1002/sim.7223 · Cited by 183
Harden, C. L., Pennell, P. B., Koppel, B. S., Hovinga, C. A., Gidal, B., Meador, K. J., Hopp, J., Ting, T. Y., Hauser, W. A., Thurman, D., et al. (2009) · Epilepsia · doi:10.1111/j.1528-1167.2009.02130.x · Cited by 170
Child development following in utero exposure: Levetiracetam vs sodium valproate
Shallcross, R., Bromley, R. L., Irwin, B., Bonnett, L. J., Morrow, J., & Baker, G. A. (2011) · Neurology · doi:10.1212/wnl.0b013e3182088297 · Cited by 161 · cited 1×
“Our results are supported by findings from a cohort study, which found that children exposed to levetiracetam were not at increased risk for delayed development compared with unexposed children (see online supplementary appendix C).(42) As indicated in the online supplementary appendix C, we were unable to include thi…”
ResultBayesian Measures of Model Complexity and Fit
Spiegelhalter, D. J., Best, N. G., Carlin, B. P., & Van Der Linde, A. (2002) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/1467-9868.00353 · Cited by 151 · cited 1×
“24 25 All analyses were conducted in OpenBUGS 26 assuming non-informative priors for all model parameters, and τ ~ Ν (0,1), τ >0.”
MethodCameron, C., Fireman, B., Hutton, B., Clifford, T., Coyle, D., Wells, G., Dormuth, C. R., Platt, R., & Toh, S. (2015) · Systematic Reviews · doi:10.1186/s13643-015-0133-0 · Cited by 140
Self-citationAntiepileptic drugs and pregnancy outcomes
Wlodarczyk, B. J., Palacios, A. M., George, T. M., & Finnell, R. H. (2012) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.35438 · Cited by 138 · cited 1×
“However, there is a lack of sufficiently powered studies to assess the impact of AEDs on neurodevelopment in children of women exposed to these agents, especially for newer-generation drugs, thus highlighting the need for a systematic review.(9) 10 The aim of this study was to compare the safety of AEDs and assess the…”
BackgroundVeiby, G., Engelsen, B. A., & Gilhus, N. E. (2013) · JAMA Neurology · doi:10.1001/jamaneurol.2013.4290 · Cited by 138 · cited 1×
“No significant differences in social impairment were identified.(41)”
BackgroundIncorporating data from various trial designs into a mixed treatment comparison model
Schmitz, S., Adams, R., & Walsh, C. (2013) · Statistics in Medicine · doi:10.1002/sim.5764 · Cited by 121 · cited 1×
“47 48 The use of observational studies allows the assessment of the safety profile of AED treatments and offers the opportunity to evaluate effects in pregnancy.”
BackgroundBanach, R., Boskovic, R., Einarson, T., & Koren, G. (2010) · Drug Safety · doi:10.2165/11317640-000000000-00000 · Cited by 105
Seizure Disorders and Pregnancy
Dalessio, D. J. (1985) · New England Journal of Medicine · doi:10.1056/nejm198502283120906 · Cited by 93
Beyene, J., Kibret, T., & Richer, D. (2014) · Clinical Epidemiology · doi:10.2147/clep.s69660 · Cited by 77 · cited 1×
“31 45 As such, the effect sizes need to be taken into account when considering the SUCRA values.”
BackgroundA scoping review of indirect comparison methods and applications using individual patient data
Veroniki, A. A., Straus, S. E., Soobiah, C., Elliott, M. J., & Tricco, A. C. (2016) · BMC Medical Research Methodology · doi:10.1186/s12874-016-0146-y · Cited by 64 · cited 1×
“An individual patient data NMA would likely provide further clarity to the field, which allows the tailoring of management to specific patient characteristics.(51)”
BackgroundSelf-citationNeurodevelopmental effects of fetal antiepileptic drug exposure
Velez-Ruiz, N. J., & Meador, K. J. (2015) · Drug Safety · doi:10.1007/s40264-015-0269-9 · Cited by 48
Tolerability of new antiepileptic drugs: a network meta-analysis
Zaccara, G., Giovannelli, F., Giorgi, F. S., Franco, V., Gasparini, S., & Benedetto, U. (2017) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-017-2245-z · Cited by 48 · cited 1×
“An NMA of 195 RCTs (including 28 013 both male and female patients) showed that gabapentin and levetiracetam showed the best tolerability profile compared with other AEDs, whereas oxcarbazepine and topiramate had a higher withdrawal rate, and lamotrigine an intermediate withdrawal rate.(43) Across all outcomes, valpro…”
Katz, J. M., Pacia, S. V., & Devinsky, O. (2001) · Epilepsy & Behavior · doi:10.1006/ebeh.2001.0158 · Cited by 38 · cited 1×
“Four of the studies included in this analysis were conference abstracts with usable data, 32–35 and four studies, 36–39 not captured in the original literature search, were identified through reference scanning.”
BackgroundDevelopment and growth in children of epileptic mothers: A prospective controlled study
Gaily, E. K. (1991) · Acta Obstetricia Et Gynecologica Scandinavica · doi:10.3109/00016349109007932 · Cited by 14
Tricco, A. C., Cogo, E., Veroniki, A. A., Soobiah, C., Hutton, B., Hemmelgarn, B. R., Moher, D., Finkelstein, Y., & Straus, S. E. (2014) · Systematic Reviews · doi:10.1186/2046-4053-3-68 · Cited by 13
Self-citationPO-0834 Long-term Developmental Outcome Of Children Prenatally Exposed To Antiepileptic Drugs
Gogatishvili, N., Ediberidze, T., Lomidze, G., Tatishvili, N. N., & Kasradze, S. (2014) · doi:10.1136/archdischild-2014-307384.1466 · Cited by 1
Miškov, S., Juraški, R. G., Fucic, A., Ivičević-Bakulić, T., Mikula, I., Cvitanović-Šojat, L., Bošnjak, J., & Demarin, V. (2009) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(09)70974-8 · Cited by 1
Research works printed but not linked: 2
- Bromley R , Baxter N , Calderbank R , et al . A comprehensive review of the language abilities of children exposed to valproate or carbamazepine in utero. Texas: American Epilepsy Society, 2010.
- Gogatishvili N , Ediberidze T , Lomidze G , et al . Cognitive outcomes of children with fetal antiepileptic drug exposure at the age of 3-6 years-preliminary data. 1st 624 Congress of the European Academy of Neurology. Berlin: European Journal of Neurology, 2015:p.329.
Cited by
Barnes, T. R., Drake, R., Paton, C., Cooper, S. J., Deakin, B., Ferrier, I. N., Gregory, C. J., Haddad, P. M., Howes, O. D., Jones, I., et al. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881119889296 · Cited by 606
The contribution of environmental exposure to the etiology of autism spectrum disorder
Bölte, S., Girdler, S., & Marschik, P. B. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-018-2988-4 · Cited by 509
Development of prefrontal cortex
Kolk, S. M., & Rakic, P. (2022) · Neuropsychopharmacology · doi:10.1038/s41386-021-01137-9 · Cited by 378
Bjørk, M.-H., Zoega, H., Leinonen, M. K., Cohen, J. M., Dreier, J. W., Furu, K., Gilhus, N. E., Gissler, M., Hálfdánarson, Ó., Igland, J., et al. (2022) · JAMA Neurology · doi:10.1001/jamaneurol.2022.1269 · Cited by 267
30 years of second-generation antiseizure medications: impact and future perspectives
Perucca, E., Brodie, M. J., Kwan, P., & Tomson, T. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30035-1 · Cited by 261
Metadata
- Authors
- Veroniki, A. A., Rios, P., Cogo, E., Straus, S. E., Finkelstein, Y., Kealey, R., Reynen, E., Soobiah, C., Thavorn, K., Hutton, B., Hemmelgarn, B. R., Yazdi, F., D'Souza, J., MacDonald, H., & Tricco, A. C.
- Affiliations
- St. Michael's Hospital (CA)
- University of Toronto (CA)
- University of Ottawa (CA)
- University of Calgary (CA)
- Corresponding author
- Tricco, Andrea C
- ORCID
- Venue
- BMJ Open
- Publisher
- BMJ
- Published
- 2017-07
- Volume
- 7
- Issue
- 7
- Pages
- e017248
- ISSN
- 2044-6055 (ISSN-L)
- PMC
- PMC5642793
- OpenAlex
- W2738349700
- Semantic Scholar
- 1927e1fe6c2f75e9ef202e803e3ecae9efc82d24
- Cited by
- 222
- References
- 50
- Citations by year
- 2026: 7 · 2025: 22 · 2024: 22 · 2023: 14 · 2022: 41 · 2021: 29 · 2020: 47 · 2019: 26 · 2018: 12 · 2017: 1
- FWCI
- 4.41
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc
- Locations
- BMJ Open (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- HighWire Press Open Archive (submittedVersion)
- Funders
- CIHR/DSEN New Investigator Award in Knowledge Synthesis
- Tier 1 Canada Research Chair in Knowledge Translation
- Tier 2 Canada Research Chair in Knowledge Synthesis
- Canadian Institutes for Health Research/Drug Safety and Effectiveness Network
- Banting Postdoctoral Fellowship Program from the CIHR
- Alberta Heritage Foundation for Medical Research
- Topics
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmacological Effects and Toxicity Studies
- Health Sciences › Medicine › Clinical Neurology › Epilepsy research and treatment
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Fetal and Pediatric Neurological Disorders
- Keywords
- antiepileptic drugs, prenatal drug exposure, breastfeeding, developmental neurotoxicity, autism spectrum disorder, cognitive delay, valproic acid, lamotrigine, oxcarbazepine, attention deficit hyperactivity disorder, neonatal seizures, epilepsy in pregnancy, drug safety comparison
- MeSH terms
- Lamotrigine, Oxcarbazepine, Anticonvulsants, Autistic Disorder, Bayes Theorem, Breast Feeding, Carbamazepine, Child, Epilepsy, Female, Humans, Pregnancy, Pregnancy Complications, Prenatal Exposure Delayed Effects, Triazines, Valproic Acid, Observational Studies as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.